This self-paced, asynchronous workshop will help you learn how to navigate business meals with ease and professionalism. Explore at your own pace—anytime, anywhere. Each semester, the Office of the ...

The combination of PD-L1 and CTLA-4 inhibition improves disease-free survival after surgery in patients with primary renal cell carcinoma, a phase 3 trial finds. For patients with renal cell carcinoma ...

Less than half of the healthcare providers correctly identified refractory chronic cough (RCC) as a cough lasting more than 8 weeks and not responding to treatment, based on survey data from more than ...

Expert DIYer April Wilkerson upgrades her workshop by showing how to get stronger and more reliable Wi-Fi coverage. Kansas mayor hit with criminal charges for allegedly voting as noncitizen in several ...

Rockland's Senior Fair, hosted at SUNY Rockland Community College's fieldhouse, takes place Sept. 17. Rocklanders can get free flu shots, blood pressure checks, smoke alarms and more. The annual event ...

CABOMETYX remains the leading TKI in renal cell carcinoma, driving strong revenue growth and expanding into new indications like neuroendocrine tumors. Exelixis's pipeline, led by zanzalintinib, shows ...

Prospective evidence supports SABR as a valid option for localized RCC and suggests SABR with or without immunotherapy has promise in the metastatic setting. Challenging notions of renal cell ...

Camlipixant showed significant efficacy in patients with higher baseline cough frequency, despite not meeting the primary endpoint in the overall population. The trial demonstrated camlipixant's ...

Real-world data gathered from the U.S. Oncology Network suggested that outcomes with first-line nivolumab plus ipilimumab (1L NIVO+IPI) in patients with metastatic renal cell carcinoma (mRCC) are ...

Bavencio and Inlyta combination therapy demonstrated high six- and 12-month OS rates in advanced RCC patients in real-world settings. The AVION study confirmed the combination's safety, with 83.7% ...

Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study. This is an ASCO Meeting Abstract from the 2025 ASCO ...